Carbapenem Market Share, Size, Trends, Industry Analysis Report, By Product Type (Meropenem, Doripenem, Imipenem, Tebipenem, And Others); By Sales Channel; By Region; Segment Forecast, 2022 - 2030

Carbapenem Market Share, Size, Trends, Industry Analysis Report, By Product Type (Meropenem, Doripenem, Imipenem, Tebipenem, And Others); By Sales Channel; By Region; Segment Forecast, 2022 - 2030

The global carbapenem market size is expected to reach USD 5.7 billion by 2030, according to a new study by Polaris Market Research. The report “Carbapenem Market Share, Size, Trends, Industry Analysis Report; By Product Type (Meropenem, Doripenem, Imipenem, Tebipenem, And Others); By Sales Channel; By Region; Segment Forecast, 2022 – 2030” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Generic versions of antibiotics are popular due to their availability and affordability. In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs. The focus of generic drug producers is to increase the reach of these drugs.

Moreover, the shortage of antibiotics to treat bacterial infections is also one of the prime factors driving the market’s growth. The increased production of generic carbapenem-based antibiotics has increased drug availability in various low- and middle-income countries.

North America is expected to grow steadily due to the increased adoption of carbapenem-based antibiotics, a high antibiotic prescription rate, and advances in research and development leading to the emergence and launch of new medicines.

However, the Asia Pacific market is expected to grow the fastest in the coming years. The carbapenem-based antibiotics market in India and China is expected to grow rapidly due to factors such as the large population, increased focus of major players on developing novel vaccines and products at affordable prices, and high market penetration of market players manufacturing generic drugs.

Furthermore, the growing number of generic players on the market hastened generic drug production. Many Asian companies are working to develop active pharmaceutical ingredients (API), which are needed to manufacture generic carbapenem-based antibiotics.

JW Pharmaceutical, a South Korean company, announced in June 2021 that it had completed production of its API for Ertapenem injection and had shipped it to the United States. In the coming years, the company intends to enter the global carbapenem antibiotic market. Furthermore, the company intends to expand Imipenem and Meropenem API and finish drug sales by exporting them to over 40 countries, including China and Japan. As a result, companies are speeding up generic drug production and propelling the global carbapenem-based antibiotics market forward.

According to a report from the Centers for Disease Control and Prevention (CDC), patients receiving immunosuppressive therapy are particularly vulnerable to hospital-acquired pneumonia (HAP). As the number of hospital-acquired pneumonia cases rises, particularly among patients with other chronic diseases such as cancer, the demand for broad-spectrum antibiotics for treatment will rise, accelerating sales of carbapenem-based antibiotics.

As the number of hospital-acquired bacterial illnesses rises, so will the demand for carbapenem-based antibiotics for pneumonia and other infections. High demand for carbapenem-based antibiotics in hospitals before surgery will drive the market.

According to a World Health Organization report, there is a global shortage of antibiotic resistance bacterial infection treatments. These worries will increase demand for generic carbapenem-based antibiotics, which are used to treat conditions such as urinary tract infections, bacterial meningitis, and other infections. Due to their low cost, these generic carbapenem antibiotics are affordable in low-income nations.

Carbapenem Market Report Highlights

  • Hospital held the largest segment in the sales channel segment with rising infections and adaptation of generic treatments.
  • North America held the dominant position because of high prescription rate of antibiotics and advancements in research and development leading to the emergence and launch of new medicines.
  • The global market is highly competitive owing to the existence of large market players with a global presence, including Spero Therapeutics, Inc., Savior Lifetec Corporation, Meiji Seika Pharma Co., Ltd., Merck & Co., Inc., Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.), Aurobindo Pharma Ltd., Daewoong Pharmaceutical Co., Ltd., Iterum Therapeutics plc, ACS Dobfar S.P.A.

  • Polaris Market Research has segmented the carbapenem market report based on product type, sales channel and region:

    Carbapenem, Product Type Outlook (Revenue – USD Billion, 2022 – 2030)
  • Meropenem
  • Imipenem
  • Doripenem
  • Tebipenem
  • Others

  • Carbapenem, Sales Channel Outlook (Revenue – USD Billion, 2022 – 2030)
  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

  • Carbapenem, Regional Outlook (Revenue – USD Billion, 2022 – 2030)
  • North America
  • U.S
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

  • 1. Introduction
    1.1. Report Description
    1.1.1. Objectives of the Study
    1.1.2. Market Scope
    1.1.3. Assumptions
    1.2. Stakeholders
    2. Executive Summary
    2.1. Market Highlights
    3. Research Methodology
    3.1. Overview
    3.1.1. Data Mining
    3.2. Data Sources
    3.2.1. Primary Sources
    3.2.2. Secondary Sources
    4. Global Carbapenem Market Insights
    4.1. Carbapenem Market – Industry Snapshot
    4.2. Carbapenem Market Dynamics
    4.2.1. Drivers and Opportunities
    4.2.1.1. Rising prevalence of infectious diseases
    4.2.1.2. Increase in empiric carbapenem use
    4.2.2. Restraints and Challenges
    4.2.2.1. Expensive process
    4.3. Porter’s Five Forces Analysis
    4.3.1. Bargaining Power of Suppliers (Moderate)
    4.3.2. Threats of New Entrants: (Low)
    4.3.3. Bargaining Power of Buyers (Moderate)
    4.3.4. Threat of Substitute (Moderate)
    4.3.5. Rivalry among existing firms (High)
    4.4. PESTLE Analysis
    4.5. Carbapenem Industry trends
    4.6. Value Chain Analysis
    4.7. COVID-19 Impact Analysis
    5. Global Carbapenem Market, by Product Type
    5.1. Key Findings
    5.2. Introduction
    5.2.1. Global Carbapenem, by Product Type, 2018 - 2030 (USD Billion)
    5.3. Meropenem
    5.3.1. Global Carbapenem Market, by Meropenem, by Region, 2018 - 2030 (USD Billion)
    5.4. Imipenem
    5.4.1. Global Carbapenem Market, by Imipenem, by Region, 2018 - 2030 (USD Billion)
    5.5. Doripenem
    5.5.1. Global Carbapenem Market, by Doripenem, by Region, 2018 - 2030 (USD Billion)
    5.6. Tebipenem
    5.6.1. Global Carbapenem Market, by Tebipenem, by Region, 2018 - 2030 (USD Billion)
    5.7. Others
    5.7.1. Global Carbapenem Market, by Others, by Region, 2018 - 2030 (USD Billion)
    6. Global Carbapenem Market, by Sales Channel
    6.1. Key Findings
    6.2. Introduction
    6.2.1. Global Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    6.3. Hospital Pharmacies
    6.3.1. Global Carbapenem Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
    6.4. Retail Pharmacies & Drug Stores
    6.4.1. Global Carbapenem Market, by Retail Pharmacies & Drug Stores, by Region, 2018 - 2030 (USD Billion)
    6.5. Online Pharmacies
    6.5.1. Global Carbapenem Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)
    7. Global Carbapenem Market, by Geography
    7.1. Key findings
    7.2. Introduction
    7.2.1. Carbapenem Market Assessment, By Geography, 2018 - 2030 (USD Billion)
    7.3. Carbapenem Market – North America
    7.3.1. North America: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.3.2. North America: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.3.3. Carbapenem Market – U.S.
    7.3.3.1. U.S.: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.3.3.2. U.S.: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.3.4. Carbapenem Market – Canada
    7.3.4.1. Canada: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.3.4.2. Canada: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4. Carbapenem Market – Europe
    7.4.1. Europe: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.2. Europe: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4.3. Carbapenem Market – UK
    7.4.3.1. UK: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.3.2. UK: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4.4. Carbapenem Market – France
    7.4.4.1. France: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.4.2. France: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4.5. Carbapenem Market – Germany
    7.4.5.1. Germany: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.5.2. Germany: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4.6. Carbapenem Market – Italy
    7.4.6.1. Italy: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.6.2. Italy: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4.7. Carbapenem Market – Spain
    7.4.7.1. Spain: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.7.2. Spain: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4.8. Carbapenem Market – Netherlands
    7.4.8.1. Netherlands: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.8.2. Netherlands: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.4.9. Carbapenem Market – Russia
    7.4.9.1. Russia: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.4.9.2. Russia: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.5. Carbapenem Market – Asia Pacific
    7.5.1. Asia Pacific: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.5.2. Asia Pacific: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.5.3. Carbapenem Market – China
    7.5.3.1. China: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.5.3.2. China: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.5.4. Carbapenem Market – India
    7.5.4.1. India: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.5.4.2. India: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.5.5. Carbapenem Market – Malaysia
    7.5.5.1. Malaysia: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.5.5.2. Malaysia: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.5.6. Carbapenem Market – Japan
    7.5.6.1. Japan: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.5.6.2. Japan: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.5.7. Carbapenem Market – Indonesia
    7.5.7.1. Indonesia: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.5.7.2. Indonesia: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.5.8. Carbapenem Market – South Korea
    7.5.8.1. South Korea: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.5.8.2. South Korea: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.6. Carbapenem Market – Middle East & Africa
    7.6.1. Middle East & Africa: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.6.2. Middle East & Africa: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.6.3. Carbapenem Market – Saudi Arabia
    7.6.3.1. Saudi Arabia: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.6.3.2. Saudi Arabia: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.6.4. Carbapenem Market – UAE
    7.6.4.1. UAE: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.6.4.2. UAE: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.6.5. Carbapenem Market – Israel
    7.6.5.1. Israel: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.6.5.2. Israel: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.6.6. Carbapenem Market – South Africa
    7.6.6.1. South Africa: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.6.6.2. South Africa: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.7. Carbapenem Market – Latin America
    7.7.1. Latin America: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.7.2. Latin America: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.7.3. Carbapenem Market – Mexico
    7.7.3.1. Mexico: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.7.3.2. Mexico: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.7.4. Carbapenem Market – Brazil
    7.7.4.1. Brazil: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.7.4.2. Brazil: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    7.7.5. Carbapenem Market – Argentina
    7.7.5.1. Argentina: Carbapenem Market, by Sales Channel, 2018 - 2030 (USD Billion)
    7.7.5.2. Argentina: Carbapenem Market, by Product Type, 2018 - 2030 (USD Billion)
    8. Competitive Landscape
    8.1. Expansion and Acquisition Analysis
    8.1.1. Expansion
    8.1.2. Acquisitions
    8.2. Partnerships/Collaborations/Agreements/Exhibitions
    9. Company Profiles
    9.1. Spero Therapeutics, Inc
    9.1.1. Company Overview
    9.1.2. Financial Performance
    9.1.3. Product Benchmarking
    9.1.4. Recent Development
    9.2. Savior Lifetec Corporation
    9.2.1. Company Overview
    9.2.2. Financial Performance
    9.2.3. Product Benchmarking
    9.2.4. Recent Development
    9.3. Meiji Seika Pharma Co., Ltd
    9.3.1. Company Overview
    9.3.2. Financial Performance
    9.3.3. Product Benchmarking
    9.3.4. Recent Development
    9.4. Merck & Co., Inc
    9.4.1. Company Overview
    9.4.2. Financial Performance
    9.4.3. Product Benchmarking
    9.4.4. Recent Development
    9.5. Gland Pharma Ltd. (Fosun Pharmaceutical Co., Ltd.)
    9.5.1. Company Overview
    9.5.2. Financial Performance
    9.5.3. Product Benchmarking
    9.5.4. Recent Development
    9.6. Aurobindo Pharma Ltd
    9.6.1. Company Overview
    9.6.2. Financial Performance
    9.6.3. Product Benchmarking
    9.6.4. Recent Development
    9.7. Daewoong Pharmaceutical Co., Ltd
    9.7.1. Company Overview
    9.7.2. Financial Performance
    9.7.3. Product Benchmarking
    9.7.4. Recent Development
    9.8. Iterum Therapeutics plc
    9.8.1. Company Overview
    9.8.2. Financial Performance
    9.8.3. Product Benchmarking
    9.8.4. Recent Development
    9.9. ACS Dobfar S.p.A
    9.9.1. Company Overview
    9.9.2. Financial Performance
    9.9.3. Product Benchmarking
    9.9.4. Recent Development

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook
    Cookie Settings